Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 2/20 | 0.44 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.44 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.44 |
| ▸ | ACACB | O00763 | 11/20 | 0.43 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.42 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.42 |
| ▸ | PROKR1 | Q8TCW9 | 2/20 | 0.39 |
| ▸ | SPR | P35270 | 1/20 | 0.38 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4303632 | 1.00 | PRKCA (0.44) | PRKCAPRKCQPRKCDACACBHCRTR1 | |
| SCHEMBL4299128 | 1.00 | PRKCA (0.44) | PRKCAPRKCQPRKCDACACBHCRTR1 | |
| SCHEMBL4303735 | 0.95 | ACACB (0.45) | PRKCAPRKCQPRKCDACACBUSP30 | |
| SCHEMBL4303731 | 0.95 | ACACB (0.45) | PRKCAPRKCQPRKCDACACBUSP30 | |
| SCHEMBL4305001 | 0.91 | HCRTR1 (0.42) | PRKCAPRKCQPRKCDACACBHCRTR1 | |
| SCHEMBL4298258 | 0.91 | HCRTR1 (0.42) | PRKCAPRKCQPRKCDACACBHCRTR1 | |
| SCHEMBL4298265 | 0.91 | HCRTR1 (0.42) | PRKCAPRKCQPRKCDACACBHCRTR1 | |
| SCHEMBL4300154 | 0.91 | PRKCA (0.44) | PRKCAPRKCQPRKCDACACBHCRTR1 | |
| SCHEMBL4300155 | 0.91 | PRKCA (0.44) | PRKCAPRKCQPRKCDACACBHCRTR1 | |
| SCHEMBL4296322 | 0.87 | PRKCA (0.43) | PRKCAPRKCQPRKCDACACBHCRTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090197859-A1 | Pyridinyl Amides for the Treatment of CNS and Metabolic Disorders | PFIZER INC. | 2009-08-06 | — | — | US | disclosed |
| US-20090197859-A1 | Pyridinyl Amides for the Treatment of CNS and Metabolic Disorders | PFIZER INC. | 2009-08-06 | — | — | US | disclosed |
| US-20090197859-A1 | Pyridinyl Amides for the Treatment of CNS and Metabolic Disorders | PFIZER INC. | 2009-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090197859-A1 | Pyridinyl Amides for the Treatment of CNS and Metabolic Disorders | HTR6, HTR5A, TPH1 | PRKCA 3735/4885PRKCQ 2560/4885PRKCD 3188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.